Over the past several years, the approvals of five PD-1/PD-L1 inhibitors – nivolumab (Opdivo®), pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), avelumab (Bavencio®), and durvalumab (Infinzi®) – have paved the way for exploration of these immunotherapies in the treatment of advanced urothelial cancer.
At the virtual ASCO session, results of the JAVELIN Bladder 100 trial were among the most significant findings for urothelial cancer in several decades, demonstrating the potential for avelumab to become a new standard of care. The phase 3 study evaluated 700 patients with stable or responding disease on first-line chemotherapy to either avelumab as a first-line maintenance immunotherapy or observation. Patients receiving avelumab had a significantly longer median survival rate (21 months) than patients who received best supportive care (14 months). Efficacy benefits were seen across all subgroups and the safety profile of avelumab was consistent with previous studies of monotherapy. Based on these positive findings, the FDA recently approved avelumab for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, making this therapy the first medicine in the PD-1/PD-L1 class in this disease state.
For additional summaries compiled by Cardinal Health Specialty Solutions clinical experts and their colleagues, please visit our ASCO summaries landing page, featuring abstracts in myeloma, prostate cancer, leukemia, lymphoma and more.